REGENXBIO (RGNX) Set to Announce Earnings on Wednesday

REGENXBIO (NASDAQ:RGNX) will issue its quarterly earnings data after the market closes on Wednesday, November 6th. Analysts expect the company to announce earnings of ($1.16) per share for the quarter. Persons interested in participating in the company’s earnings conference call can do so using this link.

REGENXBIO Trading Up 0.6 %

NASDAQ:RGNX traded up $0.05 during mid-day trading on Tuesday, hitting $8.81. 140,192 shares of the company’s stock traded hands, compared to its average volume of 589,602. The firm has a market capitalization of $435.42 million, a price-to-earnings ratio of -1.65 and a beta of 1.23. The firm has a 50 day moving average of $10.72 and a two-hundred day moving average of $12.60. REGENXBIO has a 12 month low of $8.53 and a 12 month high of $28.80.

Insider Activity

In related news, Director Argeris N. Karabelas sold 10,000 shares of the stock in a transaction dated Tuesday, September 3rd. The shares were sold at an average price of $11.56, for a total transaction of $115,600.00. Following the completion of the sale, the director now owns 11,286 shares in the company, valued at $130,466.16. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. 13.13% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

RGNX has been the topic of a number of research reports. StockNews.com raised shares of REGENXBIO from a “sell” rating to a “hold” rating in a research report on Friday, September 20th. Chardan Capital reaffirmed a “buy” rating and set a $52.00 price objective on shares of REGENXBIO in a research report on Tuesday, October 22nd. Barclays decreased their target price on REGENXBIO from $55.00 to $50.00 and set an “overweight” rating on the stock in a research report on Monday, August 5th. HC Wainwright reaffirmed a “buy” rating and issued a $39.00 price target on shares of REGENXBIO in a report on Wednesday, September 4th. Finally, Raymond James reiterated an “outperform” rating and issued a $18.00 price objective on shares of REGENXBIO in a research report on Thursday, October 10th. Three equities research analysts have rated the stock with a hold rating and ten have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $35.45.

REGENXBIO Company Profile

REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company’s products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy.